BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 25, 2002
 |  BioCentury  |  Strategy

Lundbeck's move into the U.S.

H. Lundbeck A/S's acquisition of Synaptic Pharmaceutical Corp. was driven by the specialty pharma company's need to continue growing its early stage CNS R&D capabilities. The acquisition also provides a U.S. foothold for the CNS-focused company, which until now has not had a U.S. base of operations.

"We have been growing R&D at an aggregate rate of about 30% for about five years," said Claus Braestrup, executive vice president for R&D at Lundbeck (CSE:LUN, Copenhagen, Denmark). Indeed, the company's average annual R&D outlay has grown at 36% over the last five years. However, in 2001, R&D spending grew by only 9% (see "Lundbeck's Growth").

LUN has eight compounds in the clinic, four of which are in Phase II or Phase III,...

Read the full 600 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >